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MULTIPLE DISORDERS—HEALTH POLICY 
PMDH1
NICE REQUIREMENTS FOR COST-
EFFECTIVENESS EVIDENCE: POTENTIAL 
SAMPLE SIZE IMPLICATIONS OF GENERATING 
TRIAL-BASED EVIDENCE
Backhouse ME1, Gaffney L1, Mauskopf JA2
1Research Triangle Institute, Manchester, UK; 2Research 
Triangle Institute, Research Triangle Park, NC, USA
OBJECTIVE: NICE was established in the UK in 1999 to
make recommendations about technology adoption based
on effectiveness and cost-effectiveness evidence. The ABPI
has expressed concern that these requirements will ex-
tend product development times and increase develop-
ment costs. This will depend upon the role NICE expects
randomized controlled trials (RCTs) to play in the pro-
duction of cost-effectiveness evidence, particularly at the
time of launch. However, NICE have not yet issued de-
tailed guidance on economic evaluation methodology.
Therefore this paper assesses whether a requirement for
trial-based economic evidence would increase sample sizes
since these are a major determinant of development times
and costs. METHODS: The University of York Centre
for Reviews and Dissemination (CRD) database was used
to identify studies, which had collected economic data
alongside RCTs, presented cost-effectiveness ratios and
reported variances. Publications pertaining to them were
retrieved and the data relevant for sample size calcula-
tions were extracted. Recently published sample size for-
mulae based on the net health benefits approach were
used to calculate the number of subjects which would
have been required for testing cost-effectiveness hypothe-
ses. These were compared with those used to evaluate the
clinical outcomes in the original trials. RESULTS: For
each of the studies surveyed, sample sizes would have
been significantly greater for performing cost-effective-
ness studies than for performing the original clinical trials
of which they were a part. However, they are sensitive to
the choice of the ratio of acceptable cost-effectiveness
used in the calculations. CONCLUSIONS: If NICE issues
guidance which requires cost-effectiveness evidence based
on RCTs to be of the same standard used in the classical
approach to clinical evaluations, then the required sam-
ple sizes, and hence costs, will most likely be higher than
those required for purely clinical evaluation. Larger sam-
ple sizes are also likely to extend the period of recruit-
ment and hence development times.
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THE USE OF SURROGATE ENDPOINT DATA IN 
EVALUATING TREATMENT EFFICACY: IMPACT 
ON DECISION-MAKING AND EXPENDITURE 
WITHIN THE AUSTRALIAN PHARMACEUTICAL 
BENEFITS SCHEME
Lopert R, Hill SR, Henry DA
Discipline of Clinical Pharmacology, Faculty of Medicine and 
Health Sciences, University of Newcastle, Waratah, Australia
OBJECTIVE: To investigate the extent to which claims
of efficacy in applications for requesting the addition of
new drugs to the formulary of the Australian Pharmaceu-
tical Benefits Scheme have been based on surrogate out-
come data. METHODS: Analyses were drawn from a da-
tabase of all submissions for new drug/indication pairs
considered between 1993 and 1998. Applications were
classified according to whether the data presented were
based on clincal, intermediate or surrogate endpoints.
Drugs utilization and expenditure data were examined
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